Since the biological effects of TGF-β1 are diverse, the pathological significance of both clinical stage-dependent changes of TGF-β1 content in periphery and pathological grade-dependent changes in post-mortem brain tissues of HD patients is thought to be complex and, further studies are needed to specifically address this issue. This evidence concerns the gene TGFB1 and Huntington disease.